Geovax Labs, INC

GeoVax Labs reports Q2 2026 financial results, highlighting progress on its GEO-MVA vaccine candidate and Gedeptin immuno-oncology program, with plans for a pivotal immunobridging study in Q4 2026.

GeoVax Labs received a notice from Nasdaq indicating non-compliance with the minimum stockholders equity requirement, with a plan to regain compliance due by August 21, 2026.

GeoVax Labs, Inc. reported on its annual meeting held June 17, 2026, where stockholders elected directors and approved several warrant exercise proposals.

GeoVax Labs announced a $3 million private placement financing, issuing common stock and warrants to institutional investors.

GeoVax Labs reported first quarter 2026 financial results, highlighting progress on its GEO-MVA mpox vaccine Phase 3 trial and continued development of its Gedeptin immuno-oncology therapy.

GeoVax Labs Inc. announced a warrant inducement transaction to encourage holders of existing warrants to exercise them for cash, resulting in the issuance of new warrants.

GeoVax Labs reports reduced operating expenses in Q2 2026, with a net loss of $4.4 million, as the company prioritizes its mpox/smallpox and oncology vaccine candidates.

GeoVax Labs reports reduced operating expenses and net loss in Q1 2026, with continued focus on vaccine development and ongoing capital raising efforts.

GeoVax Labs reported increased net losses and a going concern warning for Q3 2025, despite raising significant capital and advancing its vaccine and immunotherapy pipeline.

GeoVax Labs, Inc. reported a substantial net loss and increased cash burn for Q2 2025, coupled with the termination of a key government contract, raising significant doubt about its ability to continue as a going concern, despite recent equity financings.

GeoVax Labs reports increased revenue in Q1 2025 due to a government contract but faces financial uncertainty following the contract's termination.

GeoVax Labs saw a significant increase in revenue due to a BARDA contract, while continuing to advance its vaccine and immunotherapy programs.

GeoVax Labs, Inc. filed its annual report for the fiscal year ended December 31, 2025, detailing progress in its vaccine development programs for mpox, smallpox, COVID-19, and cancer, alongside financial performance and ongoing funding needs.

GeoVax Labs' 10-K filing details the company's financial results for 2024 and provides updates on its vaccine and immunotherapy programs, including significant BARDA funding for its COVID-19 vaccine candidate.

GeoVax Labs has filed an amendment to its annual report on Form 10-K to include information required in Part III of the original filing and new certifications from its principal executive and financial officers.

GeoVax Labs Inc. has released its 10-K annual report, detailing its financial results and progress in developing vaccines and immunotherapies for infectious diseases and cancers.

GeoVax Labs Director John N. Spencer Jr. acquired 10,000 shares of common stock at $0.5498 per share, increasing his direct beneficial ownership to 21,402 shares.

GeoVax Labs' Chief Medical Officer, Kelly T. McKee Jr., acquired 1,107 shares of common stock, increasing his direct beneficial ownership.

GeoVax Labs, Inc. Director Nicole Lemerond has reported the grant of 10,000 stock options with an exercise price of $2.48, contingent on the recently approved 2025 Stock Incentive Plan.

GeoVax Labs, Inc. Director and 10% Owner Randal Chase has reported the acquisition of 10,000 stock options, deemed granted on June 5, 2025, following shareholder approval of the company's 2025 Stock Incentive Plan.

GeoVax Labs, Inc. Director Dean G. Kollintzas was granted 10,000 stock options with an exercise price of $2.48, following shareholder approval of the company's 2025 Stock Incentive Plan.

GeoVax Labs, Inc. Director Robert T. McNally was granted 10,000 stock options with an exercise price of $2.48, contingent upon and effective from the shareholder approval of the 2025 Stock Incentive Plan on June 5, 2025.

GeoVax Labs announces its 2026 Annual Meeting of Stockholders, detailing proposals for director elections, warrant exercise approvals, and auditor ratification.

GeoVax Labs, Inc. is seeking stockholder approval for the issuance of shares related to a September 2025 private placement and a reverse stock split to maintain Nasdaq listing compliance.

GeoVax Labs is holding its annual meeting to elect directors, approve a new stock incentive plan, approve the issuance of shares upon warrant exercise, and ratify the appointment of its accounting firm.

GeoVax Labs is holding a special meeting to seek stockholder approval for the issuance of common stock upon the exercise of warrants related to recent private placements, aiming to secure additional funding and comply with Nasdaq listing rules.

GeoVax Labs is convening its annual stockholder meeting on May 23, 2024, to vote on key proposals including director elections, warrant issuance approval, by-law amendments, and auditor ratification.

GeoVax Labs, Inc. has filed a registration statement for the resale of up to 7,639,967 shares of its common stock by selling stockholders.

GeoVax Labs, a clinical-stage biotechnology company, is offering up to $7.5 million in common and pre-funded units to fund operations, facing a 'going concern' opinion and recent contract termination.

GeoVax Labs files an S-1 registration statement for warrant resale, highlighting clinical advancements in vaccines and oncology therapies while facing significant financial challenges and a 'going concern' opinion.

GeoVax Labs, a clinical-stage biotechnology company, has filed an S-1/A registration statement for a public offering of up to 8,333,334 common units and pre-funded units to raise approximately $6.8 million, aiming to fund its vaccine and immunotherapy programs despite a history of operating losses and a recent contract termination.

GeoVax Labs, a clinical-stage biotechnology company, announced a public offering of up to $7.5 million in units to fund its vaccine and immunotherapy pipeline, while also disclosing the termination of a significant BARDA contract for its COVID-19 vaccine.

GeoVax Labs files an S-1 registration statement for the resale of up to 975,610 shares of common stock by a selling stockholder, derived from a recent private placement.

Jane Street Group, LLC has filed a Schedule 13G reporting a 5.6% beneficial ownership stake in GeoVax Labs, Inc.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% in GeoVax Labs, Inc. common stock as of March 31, 2026.

Intracoastal Capital LLC and associated individuals report beneficial ownership of 9.99% of GeoVax Labs' common stock as of March 31, 2026.

L1 Capital Global Opportunities Master Fund, Ltd. has reduced its beneficial ownership in GeoVax Labs, Inc. to 1.79% of common stock outstanding.

Intracoastal Capital LLC and its principals reported a 9.99% passive beneficial ownership stake in GeoVax Labs, Inc. through warrants.

Ayrton Capital LLC, along with Alto Opportunity Master Fund and Waqas Khatri, reported a 9.99% beneficial ownership stake in GeoVax Labs, primarily through warrants.